Co-Diagnostics, Inc. Enters Warrant Inducement, Seeks ~$2.67M Financing

What Happened
Co-Diagnostics, Inc. filed an 8‑K reporting that on July 30, 2026 it entered an inducement letter with holders of existing warrants to induce cash exercise of 1,702,362 existing warrants (original exercise price $1.571) in exchange for issuance of new common stock purchase warrants covering up to 3,404,724 shares at $1.56 per share. The Company expects aggregate gross proceeds of approximately $2.67 million from the warrant exercises. A placement agency agreement with Maxim Group LLC was also entered on July 30, 2026; the closing is expected on or about August 3, 2026.

Key Details

• Existing warrants: 1,702,362 shares exercisable at $1.571; expected gross proceeds ≈ $2.67M (before fees/expenses).
• New warrants: cover up to 3,404,724 shares at $1.56; not exercisable until stockholder approval per Nasdaq rules; five‑year term from approval.
• Placement agent: Maxim Group LLC; fee = 7.0% of gross proceeds plus reimbursement of up to $50,000 in expenses.
• Share count: outstanding common shares increase from 5,277,846 to 6,980,208 if the transaction closes as described.
• Registration/transfer terms: Company will file a resale registration statement for the new warrant shares within 30 days and use commercially reasonable efforts to have it effective within 60 (or 90 in case of full SEC review) days. Beneficial ownership limits of 4.99% (or elected 9.99%) apply to exercise.

Why It Matters
This transaction is a financing-driven deal that should provide Co-Diagnostics with immediate cash (≈$2.67M) while granting warrant holders additional upside via new warrants that require shareholder approval before exercise. Investors should note potential near‑term dilution if the new warrants are later exercisable and registered, the placement agent costs (7% fee + expenses), and the Nasdaq/SEC approval steps that govern when and how the new warrants can be exercised or resold.